Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxytocin, Couple Interaction and Wound Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01594775
Recruitment Status : Completed
First Posted : May 9, 2012
Last Update Posted : February 25, 2014
Sponsor:
Collaborator:
Swiss National Science Foundation
Information provided by (Responsible Party):
University of Zurich

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

effects of intranasal oxytocin and couple interaction on wound healing.

  • Trial with medicinal product

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Syntocinon (Oxytocin) nasal spray Drug: Placebo Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : October 2011
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Oxytocin

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: nasal spray Drug: Syntocinon (Oxytocin) nasal spray
two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
Placebo Comparator: Placebo Drug: Placebo
two-times daily self-administration of nasal spray containing placebo during five days after wounding.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. wound size [ Time Frame: seven days ]
    wound healing process within seven days after wounding


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • healthy heterosexual couples
  • in a stable relationship since > 1 year

Exclusion criteria: pregnancy

  • breast feeding
  • heavy smoking (> 5 cigarettes/d)
  • extensive skin disease
  • artificial UV irradiation during < 3 months before study inclusion
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01594775


Locations
Layout table for location information
Switzerland
University Hospital Zurich, Dept. of Dermatology
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Swiss National Science Foundation
Investigators
Layout table for investigator information
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
Principal Investigator: Severin Laeuchli, MD University Hospital Zurich, Division of Dermatology
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01594775    
Other Study ID Numbers: KEK-ZH-NR: 2009-0063
First Posted: May 9, 2012    Key Record Dates
Last Update Posted: February 25, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Oxytocin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs